CD3-Targeted Lentiviral Vectors for Resting T Cell Transduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current viral vectors, including lentiviral vectors, face challenges in efficiently transducing certain target cells, such as T cells, especially when they are in a resting or non-activated state.

Innovation Solution

The use of CD3-targeted viral vectors, specifically lentiviral vectors, which are designed to bind to CD3 molecules on T cells, allowing for efficient transduction of both activated and resting T cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional lentiviral vectors are used to transduce T cells, then the transduction process can be performed, but the transduction efficiency is low especially for resting or non-activated T cells

Engineering Contradiction:

Improvetransduction efficiencyVSAvoidtransduction success rate

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent modifies the viral vector by changing the targeting parameter from generic cell surface markers to CD3-specific binding agents. This parameter change enables the vector to specifically recognize and bind to CD3 molecules on T cells, thereby significantly improving transduction efficiency for both resting and activated T cells compared to conventional vectors

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces CD3 binding agents as intermediary molecules on the viral vector surface. These binding agents act as mediators that facilitate interaction between the viral vector and T cells by specifically binding to CD3 molecules, thereby enhancing the transduction process and overcoming the low efficiency observed with conventional vectors

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables effective transduction of T cells with high efficiency, even when they are in a non-activated state, potentially enhancing therapeutic applications such as cancer immunotherapy.

Implementation Method 1

contacting T cell with a lentiviral vector comprising a CD3 binding agent, wherein the lentiviral vector transduces the T cell

Methodology Applied

Scientific EffectBinding interaction: Chemical Bonding

Data Source

PatentUS20250152709A1CD3-targeted lentiviral vectors and uses thereof

Publication Date: 2025.05.15 SANA BIOTECHNOLOGY INC

AI summary

Provided herein are methods of transducing T cells using CD3-targeted viral vectors.